Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 8/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079068 | 0.94 | SMN1; SMN2 (0.44) | SMN1; SMN2CCR3CYP1A2PTGS2ABCC9 | |
| SCHEMBL5345851 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2CCR3CYP1A2 | |
| SCHEMBL13252747 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2CCR3CYP1A2ABCC9ABCC8 | |
| SCHEMBL584093 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2CCR3CYP1A2ABCC9ABCC8 | |
| SCHEMBL583651 | 0.76 | SMN1; SMN2 (0.53) | SMN1; SMN2CCR3CYP1A2ABCC9ABCC8 | |
| SCHEMBL4606507 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2CCR3CYP1A2PTGS2ALDH1A1 | |
| SCHEMBL4603388 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL4604449 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CCR3ALDH1A1KMO | |
| SCHEMBL14387911 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2CCR3CYP1A2ALDH1A1 | |
| SCHEMBL13225982 | 0.73 | SMN1; SMN2 (0.49) | SMN1; SMN2CCR3ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2417120-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
| US-20060069128-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-03-30 | — | — | US | disclosed |
| US-6992091-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1545524-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004024682-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | SMN1; SMN2 4305/4885CCR3 1/4885CYP1A2 1758/4885 |
| US-20060069128-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | SMN1; SMN2 4237/4885CCR3 13/4885CYP1A2 4168/4885 |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | SMN1; SMN2 4237/4885CCR3 13/4885CYP1A2 4168/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | SMN1; SMN2 1482/4885CCR3 1/4885CYP1A2 2935/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | SMN1; SMN2 1205/4885CCR3 1/4885CYP1A2 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.